Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227659 | 0.92 | BCHE (0.57) | BCHE | |
| SCHEMBL14648566 | 0.89 | BCHE (0.60) | BCHECHRM3 | |
| SCHEMBL4135213 | 0.84 | BCHE (0.67) | BCHEACHESMN1; SMN2MEN1KMT2A | |
| SCHEMBL8313882 | 0.84 | BCHE (0.70) | BCHEACHEMEN1KMT2A | |
| SCHEMBL17294711 | 0.84 | CHRM3 (0.70) | CHRM3 | |
| SCHEMBL12058614 | 0.84 | BCHE (0.60) | BCHECHRM3 | |
| Hydrochloric Acid SCHEMBL9380707 | 0.83 | BCHE (0.65) | BCHEACHESMN1; SMN2MEN1KMT2A | |
| SCHEMBL27756963 | 0.83 | BCHE (0.69) | BCHEACHEMEN1KMT2A | |
| SCHEMBL11473244 | 0.83 | BCHE (0.56) | BCHE | |
| SCHEMBL1034422 | 0.82 | BCHE (0.68) | BCHEACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| CN-102391251-A | Chemokine receptor antagonists | NOVARTIS AG | 2012-03-28 | — | — | CN | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| CN-1946713-A | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-04-11 | — | — | CN | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | BCHE 2386/4885ACHE 4338/4885CHRM3 580/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | BCHE 2327/4885ACHE 4358/4885CHRM3 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.